#### Article 1

### Genetic study of psoriasis highlights its close link with 2 socio-economic status and affective symptoms 3

- Anni Heikkilä<sup>1</sup>, Eeva Sliz<sup>1</sup>, Laura Huilaja<sup>2</sup>, FinnGen<sup>3</sup>, Estonian Biobank Research Team<sup>4</sup>, 4
- 5 Kadri Reis<sup>4</sup>, Priit Palta<sup>4,5</sup>, Abdelrahman G. Elnahas<sup>4</sup>, Anu Reigo<sup>4</sup>, Tõnu Esko<sup>4</sup>, Triin Laisk<sup>4</sup>,
- Maris Teder-Laving<sup>4</sup>, Kaisa Tasanen<sup>2</sup>, Johannes Kettunen<sup>1</sup> 6
- <sup>1</sup> Systems epidemiology, Research Unit of Population Health, Faculty of Medicine, and Biocenter 7
- 8 Oulu, University of Oulu, Oulu, Finland
- 9 <sup>2</sup> Department of Dermatology, Research Unit of Clinical Medicine, Medical Research Center Oulu,
- 10 Oulu, and University Hospital and University of Oulu, Oulu, Finland
- 11 <sup>3</sup> A list of FinnGen authors and their affiliations available in the supplements
- <sup>4</sup> Institute of Genomics, University of Tartu, Tartu, Estonia 12
- <sup>5</sup> Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki 13

14

## 15 Abstract

16 Psoriasis is an inflammatory skin disease with an estimated heritability of around 70 %. 17 Previous genome-wide association studies (GWASs) have detected several risk loci for 18 psoriasis. To further improve the understanding of the genetic risk factors impacting the 19 disease, we conducted a discovery GWAS in FinnGen and a subsequent replication and 20 meta-analysis with data from the Estonian Biobank and the UK biobank; the study sample 21 included 925 649 individuals (22 659 cases and 902 990 controls), the largest sample for 22 psoriasis yet. In addition, we conducted downstream analyses to find out more about 23 psoriasis' cross-trait genetic correlations and causal relationships. We report 8 novel risk 24 loci, most of which harbor genes related to nuclear factor kappa-light-chain-enhancer of 25 activated B-cells-signaling pathway and overall immunity. Genetic correlations highlight the 26 relationship between psoriasis and smoking, higher body weight, and lower education 27 level. Additionally, we report novel causal relationships between psoriasis and mood 28 symptoms, as well as two-directioned causal relationship between psoriasis and lower 29 education level. Our results provide new knowledge on psoriasis risk factors, which may 30 be useful in the development of future treatment strategies.

## 31 Introduction

32 Psoriasis is a chronic autoinflammatory disease typically manifesting as sharply 33 demarcated erythematous scaling plaques on the skin. The exact symptoms depend on 34 the subtype of the disease, the most common being psoriasis vulgaris, which affects around 90 % of the psoriasis patients<sup>1</sup>. Both genetic and environmental factors play a role 35 in psoriasis pathogenesis. Heritability has been estimated to be around 70 % in twin 36 37 studies<sup>2</sup>. Known risk loci include the human leukocyte antigen (HLA) region, especially 38 HLA-C<sup>3</sup>. Additionally, for example many nuclear factor kappa-light-chain-enhancer of 39 activated B-cells (NF-kB)-4 and interleukin (IL)-23/IL-27-signaling pathway-related genes<sup>5</sup> 40 have been associated with psoriasis. Known epidemiological risk factors affecting psoriasis risk include smoking<sup>6</sup>, obesity<sup>7</sup>, and stress<sup>8</sup>, among others. Psoriasis also has 41 42 multiple comorbidities<sup>9</sup>, including cardiovascular diseases, other inflammatory diseases, and psychiatric disorders<sup>10</sup>. 43

The aim of this study was to find new risk loci for psoriasis. To do this, we analyzed
genome-wide data of over 900 000 people from Finland (FinnGen), Estonia (The Estonian
Biobank), and United Kingdom (UK Biobank). We further utilized the newly generated

47 genome-wide results to evaluate genetic correlations and causal inferences between

- 48 psoriasis and other traits.
- 49 Materials and methods
- 50 Study populations

FinnGen (www.finngen.fi/en) is a Finnish collaboration project that several public and private partners are taking part in. The aim of the project is to collect 500 000 samples of genotype data combined with health record data from Finnish registries. We used FinnGen data freeze 7, in which there were 6 995 cases diagnosed with psoriasis (one or more diagnoses with International Classification of Diseases (ICD)-10 codes L40.0-L40.9) and 299 128 controls.

FinnGen participants provided written informed consent for biobank research, based on
the Finnish Biobank Act. More detailed description of the consents, ethics committees and
study approvals are presented in the **Supplementary Note**.

60 Estonian Biobank (EstBB) is a population-based biobank at the Institute of Genomics, 61 University of Tartu. The current cohort size is 200,000 individuals (aged  $\geq$  18), reflecting 62 the age, sex and geographical distribution of the adult Estonian population. Estonian 63 samples represent 83%, Russians 14%, and other ethnicities 3% of all participants. All 64 subjects have been recruited by general practitioners (GP), physicians in hospitals and 65 during promotional events. The EstBB database is linked with national registries (such as 66 Cancer Registry and Causes of Death Registry), hospital databases, and the database of 67 the national health insurance fund, which holds treatment and procedure service bills. 68 Diseases and health problems are recorded as ICD-10 codes and prescribed medicine 69 according to the ATC classification. These health data are continuously updated through 70 periodical linking to national electronic databases and registries. All participants were 71 genotyped with genome-wide chip arrays and further imputed with a population-specific 72 imputation panel consisting of 2,244 high-coverage (30x) whole genome sequenced 73 individuals and 16,271,975 high-quality variants<sup>11</sup>. Association analysis was conducted 74 with SAIGE<sup>12</sup> mixed models with age, sex and 10 PCs used as covariates.

75

76 Here, individuals with psoriasis were identified using the ICD-10 codes including L40.

77 EstBB GWAS analysis is supported by Personal research funding: Team grant PRG1291.

- 78 Computations were performed in the High Performance Computing Center, University of79 Tartu.
- 80 **UK Biobank** (UKBB)<sup>13</sup> is a large biobank project launched in United Kingdom, with 40 to
- 81 69 years old adults as participants. The phenotypes were identified with registry data and
- 82 questionnaires. The project is aiming to follow up participants for at least 30 years. The
- 83 PanUKBB (<u>https://pan.ukbb.broadinstitute.org/</u>) project performed a pan-ancestry genetic
- 84 analysis for 500 000 UKBB samples. We used the subset of European ancestry for this
- analysis, which consisted of 2 868 psoriasis cases and 417 663 controls.
- 86 Genotyping, imputation, and quality control
- 87 In FinnGen, the samples were genotyped using Illumina and Affymetrix arrays (Illumina
- 88 Inc., San Diego and Thermo Fischer Scientific, Santa Clara, CA, USA). Sample quality
- 89 control (QC) was performed to exclude individuals with genotype missingness of over 5 %,
- 90 ambiguous gender, excess heterozygosity (±4 SDs), and non-Finnish ancestry.
- 91 Additionally, variants with low Hardy-Weinberg equilibrium ( $p < 1 * 10^{-6}$ ), over 2 %
- 92 missingness or minor allele count under 3 %, were excluded from analysis in variant QC.
- 93 Prephasing was done using Eagle 2.3.5. Imputation was performed with Beagle 4.1., with
- 94 Finnish population specific SISu v3 reference panel. In post-imputation QC, variants with
- 95 imputation info < 0.6 were excluded from further analyses.

### 96 GWAS and meta-analysis

- 97 Psoriasis GWAS in FinnGen was performed using regenie<sup>14</sup> software. The association
- 98 model was adjusted for age, sex, the first 10 genetic principal components, and
- 99 genotyping batch.
- 100 For meta-analysis, EstBB and UKBB summary statistics were lifted from hg19 to hg38
- 101 build. A Python-based software was used for inverse-variance weighted meta-analysis
- 102 (available at <a href="https://github.com/FINNGEN/META\_ANALYSIS/">https://github.com/FINNGEN/META\_ANALYSIS/</a>). Cochran's Q-test was
- 103 performed to estimate heterogeneity.

### 104 Characterization of association signals

- 105 The association was considered novel, if there were no previous psoriasis associations
- 106 reported in a  $\pm 0.5$  MB window from the lead variant. In the novel loci, all genes in a  $\pm 0.5$
- 107 MB window from the lead variant were annotated. GenBank<sup>15</sup> and UniProt<sup>16</sup> were used to
- 108 obtain information about each gene. Additionally, broad literature research was conducted
- 109 on genes of interest. Based on this attained knowledge about the biological functions and

- 110 relevance of the genes, we aimed to find the gene most likely to have a role in the
- 111 pathogenesis of psoriasis. Further, to perform functional gene mapping and gene-based
- 112 association and enrichment tests, we run Functional Mapping and Annotation of Genome-
- 113 Wide Association Studies (FUMA)<sup>17</sup> analysis for the psoriasis summary statistics.
- Additionally, the Genotype-Tissue Expression (GTEx)<sup>18</sup> data was checked to study the 114
- 115 tissue expression of the genes of interest and to identify potential associations between
- 116 psoriasis lead variants and altered gene expression.
- 117 To estimate the SNP-based heritability and genomic inflation factor, we used the linkage 118 disequilibrium score (LDSC) pipeline tool<sup>19</sup>.
- 119 Genetic correlations
- 120 We further applied LDSC regression to estimate genetic correlations between psoriasis
- 121 and other phenotypes. We tested the correlations of psoriasis with 772 phenotypes
- 122 available in the in-house LDSC analysis pipeline. The major histocompatibility complex
- 123 was excluded from the analysis, as suggested by developers of the method<sup>20</sup>.

#### 124 Mendelian randomization

We used "TwoSampleMR" R library<sup>21,22</sup> to conduct bi-directional two-sample Mendelian 125 126 randomization between psoriasis and a selection of traits found to be genetically correlated 127 with psoriasis. To avoid sample overlap, we used FinnGen summary data to extract 128 genetic instruments for psoriasis. For other traits, we used mostly UKBB-based data 129 provided by the Medical Research Council Integrative Epidemiology Unit (MRC IEU) 130 database and implemented in the TwoSampleMR. LD clumping was performed with 131 "clump data" function and its default values, i.e., r<sup>2</sup>=0.001, a clumping window of 10 kb, 132 and European population reference. We considered the inverse-variance weighted (IVW) 133 method as the primary analysis. Egger intercepts were used to evaluate horizontal 134 pleiotropy. Additionally, we tested heterogeneity with Cochrans Q test ("mr heterogeneity") 135 and performed leave-one-out analysis ("mr leaveoneout"). A causal effect was deemed 136 significant if MR Egger estimates obtained in the sensitivity analyses were in a matching 137 direction with the IVW-estimates and false-discovery rate (FDR)-corrected p-value was 138 less than 0.05.

## 139 **Results**

### 140 Four novel psoriasis loci discovered in FinnGen

141 In the discovery GWAS conducted in FinnGen in 306 123 individuals (Figure 1A, 142 Supplementary Table S1), we found 38 genome-wide significant loci, 4 of which were 143 novel (Figure 2; Table 1): the associations at 2q32.3, 5q35.3, 7p22.1, and 16p12.1 had 144 not been associated with psoriasis in prior studies. The lead variant at 2q32.3, 145 rs77509633, is an intergenic variant near solute carrier family 39 member 10 (SLC39A10; 146 also known as ZIP10). The ZIP10 zinc carrier protein coded by this gene has been found 147 to express abnormally in patients with atopic dermatitis<sup>23</sup>. ZIP10 is also indicated to have a role in humoral immunity<sup>24</sup>. The novel association at 5g35.3, with a lead variant 148 149 rs13153019, locates near fibroblast growth factor receptor 4 (FGFR4). It acts as a receptor 150 for fibroblast growth factor 19 (FGF19), which has been found to regulate the proliferation 151 of keratinocytes in psoriasis skin <sup>25</sup>. The study also found that the inhibition of *FGFR4* 152 attenuates the effect of *FGF19* on keratinocytes. The novel association at 7p22.1, with a 153 lead variant rs748670681, is near ring finger protein 216 (RNF216), which is known to 154 participate in the regulation of the NF- $\kappa$ B signaling pathway<sup>26</sup>. At 16p12.1, the lead variant 155 rs144651842 is a missense variant in interleukin 4 receptor (IL4R), which acts as a 156 receptor for interleukins 4 and 13, both of which have been associated with psoriasis in

157 earlier GWASs<sup>5,27</sup>.

158 The novel loci detected in the discovery GWAS mostly appeared to be specific to the 159 Finnish population (Table 1; Supplementary Figure S1). The associations near RNF216 160 and *IL4R* replicated on a nominal level in EstBB (respective p-values of the lead variants in 161 the three populations: rs748670681 FinnGen 1.53 \* 10<sup>-20</sup>, EstBB 0.0074, variant not available in UKBB; rs144651842 FinnGen 2.19 \* 10<sup>-11</sup>, EstBB 0.00049, variant not 162 163 available in UKBB) whereas the associations near SLC39A10 and FGFR4 reached 164 significance in FinnGen only (respective p-values of the lead variants in the three poplations: rs77509633 FinnGen 1.93 \* 10<sup>-8</sup>, EstBB 0.064, UKBB 0.365; rs13153019 165 FinnGen 4.36 \* 10<sup>-9</sup>, EstBB 0.143, UKBB 0.186). The association signals near *RNF216* 166 167 and *IL4R* were driven by variants enriched in the Finnish population with respective 168 Finnish enrichment values of 114.849 and 119.053 calculated as ratios of the Finnish 169 allele frequency and the non-Finnish-non-Estonian European allele frequency (Table 1).

170 Meta-analysis discovers additional four novel psoriasis loci

171 In the meta-analysis of FinnGen, EstBB and UKBB, totalling up to 925 649 individuals in 172 the study (Figure 1B, Supplementary Table S2), we found altogether 57 loci associated 173 with psoriasis; of these, four loci were not reported in previous studies nor detected in the 174 discovery GWAS (Figure 3; Table 1). These included the associations at 3p12.3, 8g24.12, 175 12g24.13, and 19p13.11. In addition, the associations at 7p22.1 near RNF216 and 176 16p12.1 near ILR4 attained genome-wide significance in the meta-analysis. 177 At 3p12.3, the lead variant rs540696640 is located in the intron area of roundabout 178 homolog 1 (ROBO1). It is part of the Slit/Robo signaling pathway, which is known to affect 179 various processes including cell migration, organogenesis and angiogenesis<sup>28,29</sup>. At 180 8g24.12, the lead variant rs13264172 is in the intron area of collectin family member 10 181 (COLEC10) encoding collectin liver 1 (CL-L1), which belongs to the collectin family. 182 Collectins detect pathogens, so even though CL-L1's function is not apparent yet, it's 183 probable that it has a role in innate immunity<sup>30</sup>. Serum levels of CL-L1 and collectin kidney 184 1 (CL-K1), another collectin family member often forming a complex with CL-L1, have 185 been found to be lower in patients suffering from an autoimmune disease, systemic lupus 186 erythematosus<sup>31</sup>. At 12g24.13, the gene nearest to the lead variant rs11066283 is 187 ribosomal protein L6 (RPL6), but it has no apparent biological role in psoriasis 188 pathogenesis. A nearby TRAF-type zinc finger domain containing protein 1 (TRAFD1), 189 also known as FLN29, has a function that is strongly related to innate immunity and NF- $\kappa$ B 190 pathway<sup>32</sup>, as it has been suggested to negatively regulate Toll-like receptor (TLR) and retinoic acid-inducible gene I (RIG-I)-like pathways<sup>33</sup> and, thus, appears as a more likely 191 192 candidate to drive the psoriasis association in this locus. At 19p13.11, the lead variant 193 rs1560117 locates near leucine-rich repeat containing 25 (LRRC25), which has a role in 194 the inhibition of the NF-κB signaling pathway by promoting degradation of p65/ReIA, one 195 of NF- $\kappa$ Bs transcription factors<sup>34</sup>.

196 Of the novel loci showing genome-wide significant association with psoriasis in meta-197 analysis, only RNF216 locus showed nominally significant heterogeneity (p-value for 198 heterogeneity measured with Cochran's Q test [p-het]=0.0034; Table 1). This suggest that 199 the results were highly matching across the study populations, as also indicated by the 200 matching odds ratios (Supplementary Figure S1).

201 Psoriasis loci are enriched for inflammation-related genes

- 202 Using the psoriasis GWAS results from the meta-analysis, we performed a Multi-marker
- Analysis of GenoMic Annotation (MAGMA) enrichment analysis<sup>35</sup> as implemented in 203
- 204 FUMA<sup>17</sup>. Psoriasis loci were significantly enriched for 20 inflammation-related gene sets
- 205 (Supplementary Figure S2), including 'gene ontology (GO) cellular component (cc):
- 206 major histocompatibility complex (mhc) protein complex' ( $p = 1.45 \times 10^{-10}$ ). 'GO biological
- process (bp): cytokine-mediated signaling pathway' (p = 1.49 \* 10<sup>-8</sup>), 'GO bp: regulation of 207
- 208 defense response' ( $p = 3.68 \times 10^{-8}$ ), and 'GO bp: positive regulation of immune system process' ( $p = 1.40 \times 10^{-7}$ ). 209
- 210 **LDSC**

211 Altogether 319 genetic correlations (r<sub>a</sub>) tested with LDSC pipeline were found significant 212 after FDR correction. Psoriasis was genetically correlated with many anthropometric traits 213 (e.g., whole body fat mass  $[r_q=0.20, p=6.89 * 10^{-12}]$ , body fat percentage  $[r_q=0.20, p=1.39 * 10^{-12}]$ 214 10-<sup>11</sup>]), smoking (e.g., current tobacco smoking  $[r_q=0.29, p=3.43 \times 10^{-13}]$ ), level of 215 education (e.g., years of schooling  $[r_g=-0.25, p=8.32 * 10^{-15}]$ , qualifications: A levels/AS 216 levels or equivalent  $[r_q=-0.26, p=6.58 * 10^{-13}]$ , qualifications: college or university degree 217  $[r_q=-0.25, p=2.57 * 10^{-12}]$ , other diseases (e.g., type 2 diabetes  $[r_q=0.27, p=7.23 * 10^{-10}]$ , major depressive disorder [ $r_a$ =0.32, p=1.30 \* 10<sup>-5</sup>]) or mood (e.g., miserableness [ $r_g$ =0.19, 218 219  $p=2.08 \times 10^{-7}$ ], frequency of tiredness/lethargy in last 2 weeks [r<sub>g</sub>=0.20, p=2.86 \times 10^{-7}]) 220 (Figure 4). Additionally, correlations include many nuclear magnetic resonance (NMR)-221 based metabolic measures (e.g., ratio of linoleic acid to total fatty acids  $[r_0=-0.27, p=3.71 *$ 222  $10^{-7}$ ], ratio of polyunsaturated fatty acids to total fatty acids [r<sub>a</sub>=-0.22, p=5.30 \*10<sup>-7</sup>] and 223 ratio of polyunsaturated fatty acids to monounsaturated fatty acids  $[r_q=-0.19, p=1.06 * 10^{-1}]$ 224 <sup>5</sup>]), financial difficulties (e.g., 'illness, injury, bereavement, stress in last 2 years: financial 225 difficulties'  $[r_g=0.26, p=1.08 \times 10^{-7})$ , financial situation satisfaction  $(r_g=0.29, p=8.96 \times 10^{-7})$ , 226 'illness, injury, bereavement, stress in last 2 years: Serious illness, injury or assault to 227 yourself' ( $r_q$ =0.29, p=7.05 \* 10<sup>-6</sup>) or low age at giving birth (age at first live birth [ $r_q$ =-0.24,  $p=7.44 \times 10^{-9}$ ], age at last live birth [ $r_q=-0.22$ ,  $p=3.39 \times 10^{-6}$ ]) (**Supplementary Table S3**). 228

229

230 MR

231 We tested 99 phenotypes for causality, based on the key traits of LDSC regression results.

232 List of tested traits and studies used along with descriptions of certain traits are available

233 in Supplementary Table S4. After FDR-correction and removing traits showing significant 234 pleiotropy, differing direction of causal estimates using IVW and MR Egger methods, or if 235 the result was based on only a few SNPs, we detected altogether 9 phenotypes that are 236 causal to psoriasis and 18 that psoriasis is causal to (Figure 5, Supplementary Table S5-237 6). Results suggest that following traits are causal to psoriasis: Years of schooling (p=6.12) 238 \* 10<sup>-10</sup>), Body mass index (BMI) (4.51 \* 10<sup>-9</sup>), Whole body fat mass (4.41 \* 10<sup>-7</sup>), 239 Qualifications: College or University degree (2.68 \* 10<sup>-5</sup>), Frequency of tiredness/ lethargy 240 in last 2 weeks (1.37 \* 10<sup>-4</sup>), Inflammatory bowel disease (4.19 \*10<sup>-4</sup>), Qualifications: None of the above (1.08 \* 10<sup>-3</sup>), Triglycerides (3.17 \* 10<sup>-3</sup>) and Sleeplessness/insomnia (4.35 \* 241 242  $10^{-3}$ ). In the opposite direction, we found psoriasis to be causal to Neuroticism (1.53 \*  $10^{-3}$ ). 4), Frequency of depressed mood in last 2 weeks (1.19 \* 10-4), Suffer from 'nerves' (2.02 \* 243 244 10<sup>-4</sup>), Creatinine (enzymatic) in urine (2.41 \* 10<sup>-4</sup>), Sodium in urine (1.71 \* 10<sup>-3</sup>), Diagnoses - main ICD10: K57 Diverticular disease of intestine (1.94 \* 10<sup>-3</sup>), Qualifications: Other 245 professional qualifications eq: nursing, teaching (2.74 \* 10<sup>-3</sup>), Qualifications: None of the 246 above (3.03 \* 10<sup>-3</sup>). Age completed full time education (3.38 \* 10<sup>-3</sup>), Loneliness & isolation 247 248 (3.25 \* 10<sup>-3</sup>), Fed-up feelings (3.65 \* 10<sup>-3</sup>), Qualifications: College or university degree 249 (4.24 \* 10<sup>-3</sup>), Diagnoses - main ICD10: R10 Abdominal and pelvic pain (5.41 \* 10<sup>-3</sup>), 250 Sensitivity / hurt feelings (5.30 \* 10<sup>-3</sup>), Diagnoses - main ICD10: K80 Cholelithiasis (5.73 \* 251 10<sup>-3</sup>), Neuroticism score (6.98 \* 10<sup>-3</sup>), Apolipoprotein A-I (7.64 \* 10<sup>-3</sup>) and Qualifications: A

253

252

### 254 Discussion

levels/AS levels  $(8.29 \times 10^{-3})$ .

255 In this study, we discovered 8 novel psoriasis risk loci and replicated multiple previously 256 reported loci. Based on careful manual curation, we suggest a potential biologically 257 relevant candidate gene driving the associations at each novel locus. These genes encode 258 proteins involved in either processes in the psoriatic skin or in the regulation of immune system. In addition, we report significant genetic correlations between psoriasis and 319 259 260 other traits. We further tested some of the correlated traits for causality and report 261 evidence of causal relationship between psoriasis and mood-related symptoms and low 262 education level.

One of the most prominent psoriasis pathogenesis features is hyperproliferation of
keratinocytes<sup>1</sup>, the primary cell type found on epidermis. *FGFR4* is a fibroblast growth

factor receptor, that is expressed mainly on lungs (**Supplementary Figure S3**). It acts as a receptor for fibroblast growth factor 19 (FGF19). It has been found to activate Wnt/ $\beta$ catenin pathway<sup>25</sup>. Through this pathway, high levels of FGF19 lead to elevated beta catenin binding with TCF4, which in turn leads to keratinocyte proliferation. *FGFR4*s role was also confirmed, as its inhibition removed FGF19's promotional effect on pathway and keratinocyte proliferation. Thus, *FGFR4* has a significant role in process leading to one of the most significant characteristics of psoriatic skin.

Another known feature of psoriatic skin is excessive angiogenesis<sup>29</sup>, the formation of new 272 273 blood vessels. This process is linked with the proliferation of keratinocytes in psoriasis, as many angiogenic factors, like vascular endothelial growth factor (VEGF)<sup>36</sup> are upregulated 274 by interleukins activated in psoriasis<sup>29,37</sup>. *ROBO1*, a roundabout homolog, has the highest 275 276 expression level in fibroblasts, vagina, cervix, and skin (Supplementary Figure S4). It 277 acts as a part of the Slit/Robo signaling pathway, which is included in a wide range of 278 biological functions, including neuronal axon guidance, inflammatory cell chemotaxis and 279 angiogenesis<sup>28</sup>. Angiogenesis activity has been found to be promoted through pathway 280 including *ROBO1* and *VEGFR2*, VEGF receptor<sup>38</sup>. Thus, the found association with 281 psoriasis could be linked ROBO1's role in angiogenesis.

282 The rest of the candidate genes appear to be associated with immune system. The role of 283 immunity in psoriasis is also highlighted by the FUMA gene set enrichment results 284 (Supplementary Figure S1). The suggested roles of immune system related candidate 285 genes are various. SLC39A10, coding zinc transporter ZIP10, expresses mostly in brain 286 and thyroid (**Supplementary Figure S5**). It has been found modulate B-cell antigen 287 receptor signal transduction<sup>24</sup>, and thus, adaptive immune response. Additionally, there's 288 evidence of ZIP10 expression in skin being higher in patients with atopic dermatitis, another inflammatory cutaneous disorder<sup>23</sup>. *COLEC10*, coding CL-L1, is a pattern 289 290 recognition molecule and a member of the collectin family, expressing mainly in liver 291 (Supplementary Figure S6). It is often found in circulation in complex with another 292 collectin, COLEC11 (CL-K1). Many collectins act in pathogen detection<sup>30</sup>, and COLEC10 is 293 also suggested to have a role in immune system. For example, its low serum level associates with infections in children<sup>39</sup> and autoimmune disease systemic lupus 294 295 erythematosus<sup>31</sup>. Additionally, COLEC10 may affect skin immune homeostasis, as it might 296 have a role in neural crest cell migration and therefore possibly affect melanocyte 297 production<sup>30</sup>. *IL4R* is a receptor for interleukins 4 and 13<sup>27</sup>. Both are cytokines secreted by

298 white blood cells and have functions concerning especially immune reaction of allergens or pathogens<sup>40</sup>. Additionally, both IL4 and IL13 are important in pathogenesis of atopic 299

300 dermatitis<sup>41</sup>. The gene coding interleukin 4 has been previously found to associate with

- 301 psoriasis in GWAS<sup>5</sup>, and the molecule has long been a target of medical treatments<sup>42</sup>,
- 302 making its receptor a probable association. *IL4R* expresses most notably in lungs and
- 303 blood (Supplementary Figure S7).

304 Candidate genes LRRC25, TRAFD1 and RNF216 function on the nuclear factor kappa-305 light-chain-enhancer of B cells (NF-kB) signaling pathway, which is known to have a major 306 influence on psoriasis pathogenesis<sup>4</sup>. The NF- $\kappa$ B protein complex is known for its role in 307 immune system responses. It controls for example DNA transcription, cytokine production 308 and cell survival. Psoriatic skin contains greater levels of active NF-kB transcription factor 309 than non-psoriatic skin<sup>4,43</sup>, and it takes part in psoriasis pathogenesis by altering 310 keratinocyte and immune cell behavior. Thus, genes involved in this pathway could also 311 have an association with psoriasis. LRRC25, is a leucine-rich repeat containing molecule 312 expressing in blood (Supplementary Figure S8). Leucine-rich repeat containing 313 molecules are typically involved in immune responses<sup>44</sup>, as is LRRC25, that has been 314 found to inhibit NF-kB action through promoting autophagic degradation of p65/ReIA, one 315 of NF-κB's subunits<sup>34</sup>. This happens through LRR subunit interacting with Rel homology 316 domain in p65/ReIA and LRRC25 enhancing the interaction between p65/ReIA and p62, a 317 cargo receptor. TRAFD1 (also known as FLN29) is a negative feedback regulator gene 318 involved in immune response<sup>32</sup>, mainly expressing in lymphocytes (**Supplementary** 319 **Figure S9**). It inhibits toll-like receptor (TLR) 4 signaling and thereby also NF- $\kappa$ B<sup>32,33</sup>. TLRs are pathogen detectors and affect NF-κB action through several pathways<sup>4</sup>. TLR4, for 320 321 example, detects and lipopolysaccharides found on the surface of bacteria<sup>45</sup>, which 322 induces immune signaling and NF- $\kappa$ B activation. *RNF216* also has a role in TLR signaling. It acts as a E3 ubiquitin ligase for TLR4 and TLR9<sup>46</sup>. Ubiquitination is a process for 323 324 marking proteins for degradation. Therefore, RNF216 controls the levels of TLR4 and TLR9, through which it affects NF- $\kappa$ B signaling<sup>26,46</sup>. The gene shows highest expression in 325 testis (Supplementary Figure S10). 326

327 We report that altogether 319 phenotypes genetically correlated with psoriasis. These 328 include multiple traits related to physical activity, anthropometry, other diseases, level of 329 education, mood, pain, smoking, medication and blood metabolites. Out of the top traits,

many, such as traits related to higher disease prevalence<sup>47</sup>, smoking<sup>48</sup>, high BMI<sup>49</sup>, lower 330 level of education, and having children at a younger age<sup>50</sup> are associated with lower socio-331 332 economic status, which has previously been suggested to lead to worse psoriasis 333 symptoms<sup>51</sup>. Many of the phenotypes showing significant genetic correlation fit well with 334 previous knowledge about psoriasis' comorbidities. For example, we found multiple mood-335 related traits and for example major depressive disorder to be genetically correlated with 336 psoriasis, and many mood disorders are known to be comorbid to psoriasis<sup>52</sup>.

337 We report 27 causal relationships between psoriasis and other traits. Especially high BMI 338 and body fat mass show significant causal effect to psoriasis. This is in line with previous 339 knowledge about psoriasis risk factors and two previous MR studies<sup>53,54</sup> reporting causality between psoriasis and BMI. Additionally, our results confirm the previously detected<sup>55</sup> 340 341 causal relationship between inflammatory bowel disease (IBD) and psoriasis.

342 To the opposite direction, our results suggest psoriasis being causal to multiple mood-343 related symptoms, such as neuroticism, frequency of depressed mood or suffering from 344 'nerves'. These results may suggest that psoriasis worsens certain mood-related 345 symptoms, which may explain its known correlation with different psychiatric disorders. 346 Multiple affective disorders have been previously associated with psoriasis in 347 epidemiological settings, for example depression and anxiety are more common in 348 psoriasis patients<sup>56</sup>. Common mechanisms have been detected between affective 349 disorders and psoriasis; for example, the same pro-inflammatory cytokines levels are 350 increased<sup>57</sup> and hypothalamic-pituitary-adrenal (HPA) axis is dysregulated<sup>58</sup> in both 351 depression and psoriasis. Our results suggest that psoriasis may be causal to symptoms 352 that may partly explain the high prevalence of psychiatric disorders in psoriasis patients, 353 as these symptoms may be signs of multiple different psychiatric disorders. For example, both neuroticism<sup>59</sup> and loneliness<sup>60</sup> are associated with risk of mood and anxiety disorders. 354 355 Additionally, we found multiple diagnoses psoriasis is causal to: diverticular disease of 356 intestine, abdominal and pelvic pain and cholelithiasis. There is some previous evidence 357 possibly suggesting a connection between diverticular disease of intestine and 358 cholelithiasis with psoriasis: risk for developing diverticulitis may be a bit greater for 359 psoriasis patients<sup>61</sup>, and incidence of gallstones has been found to be associated with psoriasis and psoriatic arthritis, independent of obesity<sup>62</sup>. Such evidence was not found for 360 361 abdominal and pelvic pain, perhaps suggesting its correlation being linked to one or 362 multiple other diagnoses as a symptom.

363 Previous work has shown the epidemiological association between lower socio-economic status and worse psoriasis symptoms<sup>51</sup>. Here, our results show that education-related 364 365 traits form a noticeable amount of significant causal relationships to both directions. Thus, 366 these results seem to suggest a complex relationship between psoriasis and lower

367 education level without a definite direction for causality.

#### 368 Limitations

369 The study populations differed in the recognition of psoriasis in patients. The sample 370 prevalence of psoriasis was 6,9 % in EstBB, 2,3 % in FinnGen and 0,69 % in UKBB. 371 Possible non-identified psoriasis patients as controls may decrease statistical power to 372 detect associated loci, and the differences in psoriasis prevalence might increase the 373 heterogeneity in results. Additionally, the positive predictive value for psoriasis is 88.0 % in Finnish biobank registries<sup>63</sup> meaning uncertain psoriasis cases may influence the accuracy 374 375 of results. Some of the novel loci found in the discovery GWAS appeared to be specific to 376 the Finnish population and thus the replication of these loci in further studies would be of 377 high value. We did not consider psoriasis subtypes in our analysis. Subtypes have been 378 previously suggested to have slightly different genetic backgrounds<sup>1</sup>. Thus, the analysis of 379 the subtypes could have shed light on the exact associations and differences between 380 subgroups, that now may remain uncharacterized. Considering MR results, it should be 381 noted that we detected significant heterogeneity in multiple significant traits 382 (Supplementary Table S5-6), and results should be interpreted with care.

#### 383 Conclusion

384 To conclude, we found 8 novel psoriasis risk loci, and, overall, the present genome-wide 385 analyses emphasized the role of immune-regulating genes in the pathogenesis of 386 psoriasis. The results of the genetic correlations provided genetic evidence for the close 387 link between psoriasis and socio-economic status. With Mendelian randomization we 388 found evidence of causal relationships between obesity and psoriasis, psoriasis and mood 389 symptoms, and complex causal relationships between psoriasis and low education level. 390 Our findings deepen understanding of psoriasis and may be useful in treatment 391 development.

#### Acknowledgements 392

393 We want to acknowledge the participants and investigators of FinnGen study. Following 394 biobanks are acknowledged for delivering biobank samples to FinnGen: Auria Biobank

- 395 (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki Biobank
- 396 (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland
- 397 (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-
- 398 English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-
- 399 US/Research and development/Finnish Clinical Biobank Tampere), Biobank of Eastern
- 400 Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-
- 401 FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank
- 402 (www.veripalvelu.fi/verenluovutus/biopankkitoiminta), Terveystalo Biobank
- 403 (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) and Arctic Biobank
- 404 (https://www.oulu.fi/en/university/faculties-and-units/faculty-medicine/northern-finland-birth-
- 405 cohorts-and-arctic-biobank). All Finnish Biobanks are members of BBMRI.fi infrastructure
- 406 (www.bbmri.fi). Finnish Biobank Cooperative -FINBB (https://finbb.fi/) is the coordinator of
- 407 **BBMRI-ERIC** operations in Finland.
- 408 Estonian Biobank Research Team members: Andres Metspalu, Mari Nelis, Lili Milani,
- 409 Reedik Mägi & Tõnu Esko

#### Data availability 410

- 411 Summary statistics will be made available through the NHGRI-EBI GWAS Catalog with
- 412 GCSTxxxxxx upon publication. The Finnish biobank data can be accessed through the
- 413 Fingenious® services (https://site.fingenious.fi/en/) managed by FINBB.

#### Funding 414

- 415 ES was funded by Academy of Finland (338229) and Orion Research Foundation. JK was
- 416 funded by Sigrid Juselius foundation.
- 417 Estonian Biobank research was supported by Estonian Research Council grant PRG1291.
- 418 The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016
- 419 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK
- 420 Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene
- 421 International II Sarl), Genentech Inc., Merck Sharp & Dohme LCC, Pfizer Inc.,
- 422 GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze
- 423 Therapeutics Inc., Janssen Biotech Inc, Novartis AG, and Boehringer Ingelheim
- 424 International GmbH.

## 425 Competing interests

- 426 Dr. Huilaja has received educational grants from Takeda, Janssen-Cilag, Novartis, AbbVie
- 427 and LEO Pharma, honoraria from Lilly, Sanofi, Novartis, Abbvie, LeoPharma, Boehringel
- 428 Ingelheim and OrionPharma for consulting and/or speaking, and is an investigator for
- 429 Abbvie, Takeda and Amgen. KT has received educational grants from Novartis and
- 430 honoraria from Abbvie, Leo Pharma, Novartis, Sanofi Genzyme, Janssen-Cilag, Bristol-
- 431 Myers Squibb and UCB Pharma for consulting and/or speaking.

## 432 References

- 433 1. Rendon, A. & Schäkel, K. Psoriasis Pathogenesis and Treatment. *Int J Mol Sci* 20, 1475 (2019).
- 435 2. Lønnberg, A. S. *et al.* Heritability of psoriasis in a large twin sample. *British Journal*436 of *Dermatology* **169**, 412–416 (2013).
- 437 3. Nair, R. P. *et al.* Sequence and Haplotype Analysis Supports HLA-C as the Psoriasis
  438 Susceptibility 1 Gene. *The American Journal of Human Genetics* **78**, 827–851
  439 (2006).
- 440 4. Goldminz, A. M., Au, S. C., Kim, N., Gottlieb, A. B. & Lizzul, P. F. NF-κB: An
  441 essential transcription factor in psoriasis. *J Dermatol Sci* 69, 89–94 (2013).
- 442 5. Nair, R. P. *et al.* Genome-wide scan reveals association of psoriasis with IL-23 and
  443 NF-κB pathways. *Nat Genet* **41**, 199–204 (2009).
- Armstrong, A. W., Harskamp, C. T., Dhillon, J. S. & Armstrong, E. J. Psoriasis and
  smoking: a systematic review and meta-analysis. *British Journal of Dermatology* **170**, 304–314 (2014).
- 447 7. Jensen, P. & Skov, L. Psoriasis and Obesity. *Dermatology* **232**, 633–639 (2016).
- 448 8. Rousset, L. & Halioua, B. Stress and psoriasis. *Int J Dermatol* 57, 1165–1172
  449 (2018).
- 450 9. Gao, J., Shen, X., Ko, R., Huang, C. & Shen, C. Cognitive Process of Psoriasis and
  451 Its Comorbidities: From Epidemiology to Genetics. *Front Genet* 12, (2021).
- Ferreira, B. I. R. C., Abreu, J. L. P. D. C., Reis, J. P. G. dos & Figueiredo, A. M. D.
  C. Psoriasis and Associated Psychiatric Disorders: A Systematic Review on
  Etiopathogenesis and Clinical Correlation. *J Clin Aesthet Dermatol* 9, 36–43 (2016).
- 455 11. Mitt, M. *et al.* Improved imputation accuracy of rare and low-frequency variants using
  456 population-specific high-coverage WGS-based imputation reference panel.
  457 *European Journal of Human Genetics* 25, 869–876 (2017).
- 458 12. Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample
  459 relatedness in large-scale genetic association studies. *Nat Genet* **50**, 1335–1341
  460 (2018).

- 461 13. Sudlow, C. *et al.* UK Biobank: An Open Access Resource for Identifying the Causes
  462 of a Wide Range of Complex Diseases of Middle and Old Age. *PLoS Med* 12,
  463 e1001779 (2015).
- 464 14. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for 465 quantitative and binary traits. *Nat Genet* **53**, (2021).
- 466 15. Clark, K., Karsch-Mizrachi, I., Lipman, D. J., Ostell, J. & Sayers, E. W. GenBank.
  467 *Nucleic Acids Res* 44, (2016).
- 468 16. Bateman, A. *et al.* UniProt: the universal protein knowledgebase in 2021. *Nucleic*469 *Acids Res* 49, (2021).
- 470 17. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping
  471 and annotation of genetic associations with FUMA. *Nat Commun* 8, (2017).
- 472 18. Lonsdale, J. *et al.* The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 45, 580–585 (2013).
- 474 19. Bulik-Sullivan, B. *et al.* LD score regression distinguishes confounding from
  475 polygenicity in genome-wide association studies. *Nat Genet* 47, 291–295 (2015).
- Zheng, J. *et al.* LD Hub: A centralized database and web interface to perform LD
  score regression that maximizes the potential of summary level GWAS data for SNP
  heritability and genetic correlation analysis. *Bioinformatics* 33, 272–279 (2017).
- 479 21. Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between
  480 imprecisely measured traits using GWAS summary data. *PLoS Genet* 13, e1007081
  481 (2017).
- 482 22. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference
  483 across the human phenome. *Elife* 7, (2018).
- 484 23. Nakajima, K. *et al.* Possible involvement of zinc transporter ZIP10 in atopic
  485 dermatitis. *J Dermatol* 47, (2020).
- 486 24. Hojyo, S. *et al.* Zinc transporter SLC39A10/ZIP10 controls humoral immunity by
  487 modulating B-cell receptor signal strength. *Proceedings of the National Academy of*488 *Sciences* 111, 11786–11791 (2014).
- Yu, X., Yan, N., Li, Z., Hua, Y. & Chen, W. FGF19 sustains the high proliferative
  ability of keratinocytes in psoriasis through the regulation of Wnt/ <scp>GSK</scp> 3β/β-catenin signalling via <scp>FGFR</scp> 4. *Clin Exp Pharmacol Physiol* 46,
  761–769 (2019).
- 493 26. Xu, C. *et al.* Regulation of autophagy by E3 ubiquitin ligase RNF216 through BECN1
  494 ubiquitination. *Autophagy* **10**, 2239–2250 (2014).
- 495 27. Hahn, M. & Ghoreschi, K. The role of IL-4 in psoriasis. *Expert Rev Clin Immunol* 13, 171–173 (2017).
- 497 28. Tong, M., Jun, T., Nie, Y., Hao, J. & Fan, D. The Role of the Slit/Robo Signaling
  498 Pathway. *J Cancer* 10, 2694–2705 (2019).

- 499 29. Heidenreich, R., Röcken, M. & Ghoreschi, K. Angiogenesis drives psoriasis 500 pathogenesis. *Int J Exp Pathol* **90**, 232–248 (2009).
- 30. Wang, T., Li, K., Xiao, S. & Xia, Y. A Plausible Role for Collectins in Skin Immune
  Homeostasis. *Front Immunol* **12**, (2021).
- Troldborg, A. *et al.* Collectin liver 1 and collectin kidney 1 and other complementassociated pattern recognition molecules in systemic lupus erythematosus. *Clin Exp Immunol* 182, 132–138 (2015).
- Mashima, R. *et al.* FLN29, a Novel Interferon- and LPS-inducible Gene Acting as a
  Negative Regulator of Toll-like Receptor Signaling. *Journal of Biological Chemistry* **280**, 41289–41297 (2005).
- Sanada, T. *et al.* FLN29 Deficiency Reveals Its Negative Regulatory Role in the Tolllike Receptor (TLR) and Retinoic Acid-inducible Gene I (RIG-I)-like Helicase
  Signaling Pathway. *Journal of Biological Chemistry* 283, 33858–33864 (2008).
- 512 34. Feng, Y. *et al.* LRRC25 Functions as an Inhibitor of NF-κB Signaling Pathway by
  513 Promoting p65/RelA for Autophagic Degradation. *Sci Rep* 7, 13448 (2017).
- 51435.de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized515Gene-Set Analysis of GWAS Data. PLoS Comput Biol 11, e1004219 (2015).
- 516 36. Nofal, A., Al-Makhzangy, I., Attwa, E., Nassar, A. & Abdalmoati, A. Vascular
  517 endothelial growth factor in psoriasis: an indicator of disease severity and control.
  518 *Journal of the European Academy of Dermatology and Venereology* 23, 803–806
  519 (2009).
- 52037.Midde, H. S. *et al.* Interleukin-9 serves as a key link between systemic inflammation521and angiogenesis in psoriasis. *Clin Exp Dermatol* **46**, 50–57 (2021).
- 522 38. Li, S. *et al.* Slit2 Promotes Angiogenic Activity Via the Robo1-VEGFR2-ERK1/2
  523 Pathway in Both In Vivo and In Vitro Studies. *Invest Ophthalmol Vis Sci* 56, 5210–
  524 5217 (2015).
- 525 39. Ingels, C. *et al.* The pattern recognition molecule collectin-L1 in critically ill children.
  526 *Pediatr Res* 80, 237–243 (2016).
- 527 40. Junttila, I. S. Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and
  528 IL-13 Receptor Complexes. *Front Immunol* 9, 888 (2018).
- Matsunaga, M. C. & Yamauchi, P. S. IL-4 and IL-13 Inhibition in Atopic Dermatitis. J
   *Drugs Dermatol* 15, 925–9 (2016).
- 531 42. Ghoreschi, K. *et al.* Interleukin-4 therapy of psoriasis induces Th2 responses and
  532 improves human autoimmune disease. *Nat Med* 9, 40–46 (2003).
- 43. Lizzul, P. F. *et al.* Differential expression of phosphorylated NF-κB/RelA in normal
  and psoriatic epidermis and downregulation of NF-κB in response to treatment with
  etanercept. *Journal of Investigative Dermatology* **124**, 1275–1283 (2005).
- 536 44. Ng, A. & Xavier, R. J. Leucine-rich repeat (LRR) proteins: Integrators of pattern
  537 recognition and signaling in immunity. *Autophagy* 7, 1082–1084 (2011).

- 538 45. Lu, Y.-C., Yeh, W.-C. & Ohashi, P. S. LPS/TLR4 signal transduction pathway. 539 *Cytokine* **42**, 145–151 (2008).
- 540 46. Chuang, T.-H. & Ulevitch, R. J. Triad3A, an E3 ubiquitin-protein ligase regulating 541 Toll-like receptors. *Nat Immunol* **5**, 495–502 (2004).
- 542 47. Dalstra, J. *et al.* Socioeconomic differences in the prevalence of common chronic
  543 diseases: an overview of eight European countries. *International Epidemiological*544 *Association International Journal of Epidemiology* **34**, 316–326 (2005).
- 545 48. Hiscock, R., Bauld, L., Amos, A., Fidler, J. A. & Munafò, M. Socioeconomic status 546 and smoking: a review. *Ann N Y Acad Sci* **1248**, 107–23 (2012).
- 547 49. Morgenstern, M., Sargent, J. D. & Hanewinkel, R. Relation Between Socioeconomic
  548 Status and Body Mass Index. *Arch Pediatr Adolesc Med* 163, 731–8 (2009).
- 549 50. van Roode, T., Sharples, K., Dickson, N. & Paul, C. Life-Course Relationship
  between Socioeconomic Circumstances and Timing of First Birth in a Birth Cohort.
  551 *PLoS One* **12**, 170170 (2017).
- 552 51. Mahé, E. *et al.* Socioeconomic Inequalities and Severity of Plaque Psoriasis at a
  553 First Consultation in Dermatology Centers. *Acta Dermato Venereologica* 97, 632–
  554 638 (2017).
- 555 52. Huilaja, L., Tiri, H., Jokelainen, J., Timonen, M. & Tasanen, K. Patients with
  556 Hidradenitis Suppurativa Have a High Psychiatric Disease Burden: A Finnish
  557 Nationwide Registry Study. *Journal of Investigative Dermatology* **138**, 46–51 (2018).
- 558 53. Budu-Aggrey, A. *et al.* Evidence of a causal relationship between body mass index 559 and psoriasis: A mendelian randomization study. *PLoS Med* **16**, e1002739 (2019).
- 560 54. Ogawa, K. *et al.* A Transethnic Mendelian Randomization Study Identifies Causality
  561 of Obesity on Risk of Psoriasis. *Journal of Investigative Dermatology* **139**, 1397–
  562 1400 (2019).
- 55. Freuer, D., Linseisen, J. & Meisinger, C. Association Between Inflammatory Bowel
  564 Disease and Both Psoriasis and Psoriatic Arthritis. *JAMA Dermatol* (2022)
  565 doi:10.1001/jamadermatol.2022.3682.
- 566 56. Dalgard, F. J. *et al.* The Psychological Burden of Skin Diseases: A Cross-Sectional
  567 Multicenter Study among Dermatological Out-Patients in 13 European Countries.
  568 *Journal of Investigative Dermatology* **135**, 984–991 (2015).
- 569 57. Ayasse, M. T., Buddenkotte, J., Alam, M. & Steinhoff, M. Role of neuroimmune 570 circuits and pruritus in psoriasis. *Exp Dermatol* **29**, 414–426 (2020).
- 571 58. Evers, A. W. M. *et al.* How stress gets under the skin: cortisol and stress reactivity in 572 psoriasis. *British Journal of Dermatology* **163**, 986–991 (2010).
- 573 59. Widiger, T. A. & Oltmanns, J. R. Neuroticism is a fundamental domain of personality 574 with enormous public health implications. *World Psychiatry* **16**, 144–145 (2017).
- 575 60. Mann, F. *et al.* Loneliness and the onset of new mental health problems in the general population. *Soc Psychiatry Psychiatr Epidemiol* **57**, 2161–2178 (2022).

- 577 61. Lee, E. B., Amin, M., Duan, L., Egeberg, A. & Wu, J. J. Risk for appendicitis,
  578 cholecystitis, or diverticulitis in patients with psoriasis. *Cutis* **103**, 175-179;E1;E2
  579 (2019).
- 580 62. Tong, L. X. *et al.* Personal history of gallstones and risk of incident psoriasis and
  psoriatic arthritis in U.S. women. *British Journal of Dermatology* **172**, 1316–1322
  (2015).
- 583 63. Haverinen, S. *et al.* Validation of Psoriasis Diagnoses Recorded in Finnish Biobanks.
  584 *Acta Dermato Venereologica* **100**, adv00297 (2020).

585

# **Table 1.** Novel psoriasis risk loci in the discovery GWAS (FinnGen) and meta-analysis.

587


Associations significant in both discovery GWAS and meta-analysis (in loci 7p22.1 and 16p12.1) are underlined.

locus	chr:pos	rsid	ref	alt	gene	fin enr.	cohort	OR	95 % CI	р	af alt	p-het
2q32.3	2:195206980	rs77509633	т	с	SLC39A10	0.644	FinnGen	0.72	0.64-0.81	1.93E-08**	0.0262	
							EstBB	0.92	0.84-1	0.064	0.0296	
							UKBB	1.07	0.92-1.24	0.365		
							meta	0.88	0.83-0.94	6.01E-05*	0.0275	5.25E-05
	3:79183649	rs540696640	т	с	ROBO1	0.052	FinnGen	1.91	1.2-3.04	0.0064*	0.001	
3p12.3							EstBB	1.91	1.42-2.57	2.03E-05*	0.0021	
							UKBB	1.67	1.14-2.44	0.0082*		
							meta	1.83	1.49-2.26	1.35E-08**	0.0014	0.850
	5:177355217	rs13153019	т	с	RGS14 (FGFR4)	1.028	FinnGen	1.12	1.08-1.16	4.36E-09**	0.2723	
5q35.3							EstBB	1.02	0.99-1.06	0.143	0.2344	
							UKBB	1.04	0.98-1.11	0.186		
							meta	1.06	1.04-1.08	3.81E-07*	0.2574	0.0019
	<u>7:5397122</u>	<u>rs748670681</u>	<u>C</u>	I	<u>TNRC18 (RNF216)</u>	<u>114.849</u>	FinnGen	1.47	1.36-1.6	1.53E-20**	<u>0.0359</u>	
7-22.1							EstBB	1.18	1.05-1.34	0.0074*	<u>0.0125</u>	
<u>7p22.1</u>							UKBB	NA	NA	NA		
							meta	1.38	1.29-1.47	3.13E-20**	0.0267	0.0034
	8:119000622	rs13264172	т	A	COLEC10	0.988	FinnGen	0.92	0.89-0.95	2.23E-06*	0.5309	
8q24.12							EstBB	0.95	0.93-0.98	3.55E-04*	0.5279	
							UKBB	0.98	0.93-1.04	0.519	0.5297	
							meta	0.95	0.93-0.96	2.46E-08**		0.108
	12:112402962	rs11066283	А	G	RPL6 (TRAFD1)	0.88	FinnGen	1.08	1.04-1.12	1.34E-05*	0.379	
12q24.13							EstBB	1.05	1.02-1.08	7.17E-04*	0.4053	
							UKBB	1.08	1.02-1.14	0.006*		
							meta	1.06	1.04-1.08	1.97E-09**	0.2944	0.379
<u>16p12.1</u>	<u>16:27344903</u>	<u>rs144651842</u>	<u>G</u>	A	<u>IL4R</u>	<u>119.053</u>	FinnGen	1.23	1.16-1.3	2.19E-11**	<u>0.078</u>	
							EstBB	1.17	1.07-1.27	4.90E-04*	<u>0.0254</u>	
							UKBB	NA	NA	NA		
							meta	1.21	1.15-1.27	7.21E-14**	0.0573	0.334
19p13.11	19:18402122	rs1560117	с	т	LRRC25	1.124	FinnGen	1.06	1.02-1.09	0.0013*	0.5344	
							EstBB	1.05	1.02-1.08	3.16E-04*	0.4935	
							UKBB	1.1	1.04-1.16	3.92E-04*		
							meta	1.06	1.04-1.08	6.05E-09**	0.5183	0.342

Ref, reference allele; alt, alternative allele (effect allele); fin enr., Finnish enrichment of lead variant; af alt, alternative allele
frequency; OR, odds ratio; CI, confidence interval; p, p-value; p-het, heterogeneity p-value for meta-analysis; EstBB, Estonian
BioBank; UKBB, UK Biobank.

591 The column 'gene' reports the nearest gene and, when different from the nearest gene, a biologically relevant candidate gene in 592 brackets. Genes: *SLC39A10*, solute carrier family 39 member 10; *ROBO1*, roundabout homolog 1; *RGS14*, regulator of G protein 593 signaling 14; *FGFR4*, fibroblast growth factor receptor 4; *TNRC18*, trinucleotide repeat-containing 18; *RNF216*, ring finger protein 594 216; *COLEC10*, collectin family member 10; *RPL6*, ribosomal protein L6; *TRAFD1*, TRAF-type zinc finger domain containing protein 595 1; *IL4R*, interleukin 4 receptor; *LRRC25*, leucine rich repeat containing 25.

- 596 af\_alt values for meta are weighted means of FinnGen and EstBB frequencies, as UKBB allele frequencies were not available.
- 597 \*Nominally significant associtations: p<0.05
- 598 \*\*Genome-wide significant associations: p<5E-08




600

### Figure 1A-B. Manhattan plots of A) FinnGen-based discovery 601


### GWAS and B) FinnGen, EstBB (Estonian BioBank) and UKBB (UK 602 Biobank) meta-analysis GWAS.

# 603

- Candidate genes and rs-numbers for novel lead variants are marked in each plot. Y-axis 604 represents the -log10 p-value. The genome-wide significance threshold is marked with 605 606 dashed horizontal line.
- 607
- 608
- 609
- 610



- Figure 2A-D. Regional association plots (LocusZooms) of the
- discovery GWAS (FinnGen-only) novel risk loci (±0.5 MB around
- lead variant) at: A) 2q32.3, B) 5q35.3, C) 7p22.1, D) 16p12.1.
- Candidate genes are circled in the figures with red dashed line.



- Figure 3A-F. Regional association plots (LocusZooms) of meta-624
- analysis (FinnGen, Estonian Biobank (EstBB) and UK Biobank 625
- (UKBB) novel risk loci (±0.5 MB around lead variant) at: A) 3p12.3, 626
- B) 7p22.1, C) 8q24.12, D) 12q24.13, E) 16p12.1, F) 19p13.11. 627
- Candidate genes are circled in the figures with red dashed line. 628

Whole body fat-free mass Whole body fat mass Waist fat mass Waist fat mass			3.56e-03
Whole body fat mass Waistophin ratio			6.89e-12 3.82e-05 <
			3.09e-05
Pulse wave peak to peak itime Pulse wave Arterial Stiffness index	•	· · · · · · · · · · · · · · · · · · ·	1.64e-04 3.41e-04
Pulse wave peak to peak time Pulse wave Arefraid Stiffness index Pulse wave Arterial Stiffness index Parkinsoris disease			1.38e-02
Maximum near rate ouring interest test-			3.82e-05 Kii 3.09e-05 C 1.64e-04 C 3.41e-04 a 1.38e-02 a 1.96e-03 c 1.04e-02 c 3.43e-13 c 3.43e-13 c 3.43e-13 c 3.43e-13 c 3.43e-13 c 5.62e-05 c 5.64e-04 c 5.64
Current tobacco smoking-			
Current tobacco smoking Body mass index (BMI) Alcohol intake frequency.			1.34e-10 3.62e-04
Address in the requestion of the rest of t			
triglycerides Sodium in untur HOMA-IB HOMA-5 HDL cholestero- Crastinia (arturational)			4.18e-05 9.60e-03 1.22e-03
HOMAB			1.22e-03
	• • • •		6.97e-03 ar
Creatinine (enzymatic) in urine-		• • • • • • • • • • • • • • • • • • •	4.18e-05 9.60e-03 1.22e-03 6.97e-03 1.09e-06 7.26e-03 7.14e-05
apolipoprotein A-I			
vascular/neart problems diagnosed by doctor: None of the above- Vascular/neart problems diagnosed by doctor: High blood pressure-	•		3.51e-06 7.92e-06
Vascular/heart problems diagnosed by_doctor: Angina-			3.82e-05
Other serious medical condition/disability diagosed by doctor			7.23e-10 4.48e-06
Number of operations, self-reported			1.62e-05
Major depressive disorder (ICD-10 coded) - Logo-standing illness, disability or infirmity-			1.30e-05 1.31e-14
Long standing introst, sits barry standing introst, sits barry standing introst, stroker			1.14e-02
Inflammatory bowel disease Had other main concertaines			1.19e-08 6.86e-04
Eye problems/disorders: Diabetes related eye disease		· · · · · · · · · · · · · · · · · · ·	3.51e-06 7.92e-06 3.82e-05 7.23e-10 4.43e-06 1.62e-05 1.30e-05 1.31e-14 1.14e-02 1.19e-08 6.86e-04 2.34e-04 8.87e-04 4.84e-04 4.84e-04
Ever had bowel cancer's creeping			2.64e-04
Diagnoses - secondary rob to information and an information of the period		· · · · · · · · · · · · · · · · · · ·	1.43e-05
Vascular/heart problems diagnosed by doctor: None of the above available of the above Vascular/heart problems diagnosed by doctor: High blood pressure Vascular/heart problems diagnosed by doctor Number of operations, self-reported Number of operations, self-reported			8.87e-04 1.43e-05 1.48e-08 6.10e-04 0 1.01e-02 7.36e-03 0 0 0 0 0 0 0 0 0 0 0 0 0
Diagnoses - main rOD to. Wizs Offici joint discribed in ICD 10: K80 Cholelithiasis			1.01e-04 0 7.36e-03
Diagnoses - main ICD10; K57 Diverticular disease of intestine Diagnoses - main ICD10; K52 Other pon-intertive gaster entertier and edite			7.36e-03
Diagnoses - main ICD10. K21 Gastro-cesophageal reflux disease			2.01e-03 3.88e-03
Diagnoses - main ICD10: K20 Oesophagitis			6.94e-03
Diagnoses – main ICD 10, 344 Oriel infolio Obstitutive pulnionary disease Diagnoses – main ICD 10: 125 Chronic ischaemic heart disease		• • • • • • • • • • • • • • • • • • •	6.94e-03 6.94e-03 6.64e-04 2.87e-03 1.95e-02 6.47e-07 1.10e-04 1.24e-02 0.00e-05
Diagnoses - main ICD10: I20 Angina peetoris Diagnoses main ICD10: CE6 Managewurghthios di unpertoins			2.87e-03
Diagnoses - main rob to. doo monoremon planetes of upper inno-			6.47e-07
Coronăry artery disease			1.10e-04
Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor: Emphysema/chronic bronchitis-			2.300-05
Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor: Emphysema/chronic bronchits Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor: Blood clot in the Blood clot, DVT, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor: Blood clot in the			4.67e-03 2.18e-04
blood clot, b V , blonchitis, emphyseina, astrina, minitus, et zena, allergy diagnosed by doctor. blood clot in the eq (b V )			
Qualifications: Other professional qualifications eq: nursing, teaching			8.32e-15 1.65e-07 1.86e-05 1.83e-02
Qualifications: O levels/GCSEs or equivalent	· · · · · · · · · · · · · · · · · · ·		1.86e-05
Qualifications. Note of the above			2.01e-10 1.97e-04
Qualifications: CSEs or equivalent	1		1.838-02 m 2.01e-10 L 1.97e-04 c 2.57e-12 atti 6.58e-13 o 5.51e-05 o
Qualifications: A levels/AS levels or equivalent			6.58e-13
			5.51e-05
College completion	• • • • • • • • • • • • • • • • • • •		2.57e-12 2.57e-12 5.51e-05 5.04e-03 8.73e-07 1.61e-08
Years of schooling Qualifications: Other professional qualifications eg: nursing, teaching Qualifications: Olevels/GCSEs or equivalent Qualifications: NVQ or HND or HNC or equivalent Qualifications: NVG or HND or HNC or equivalent Qualifications: NOSEs or equivalent Qualifications: College or University degree Qualifications: A levels/AS levels or equivalent Intelligence College completion Age completed full time education			1.010-00
Tippitus Yes, now most or all of the time			1.78e-02 5.23e-03 9.74e-03 4.53e-04
Reason for glasses/contact lenses: For short-sightedness, i.e. only or mainly for distance viewing such as drivina. cinema etc (called 'mvoia')	• • • •		1.78e-02 5.23e-03 9.74e-03 4.53e-04 0 1.08e-02 5.55e-03
Louid music exposure frequency			4 53e-04
Tinnitus: Yes, now most or all of the time Tinnitus: Yes, but not now, but have in the past Tinnitus: Yes, but not now, but have in the past Tinnitus: Yes, but not now, but have in the past Tinnitus: Yes, but not now, but have in the past Tinnitus: Yes, now most or all of the time Tinnitus: Yes, but now, but have Tinnitus: Yes, but have Tinnitus: Yes, but now, but have Tinnitus: Yes, b			1.08e-02 D 5.55e-03 0
Wheeze or whistling in the chest in last year Forced vital capacity (FVC), Best measure Forced vital capacity (FVC) Forced expiratory volume in 1-second (FEV1), predicted percentage Forced expiratory volume in 1-second (FEV1). Forced expiratory volume in 1-second (FEV1)			2.76e-09
Forced vital capacity (FVC). Best measure			7.27e-04
Forced vipiratory volume in 1-second (FEVT). bredicted percentrade			9.60e-06 G
Forced expiratory volume in 1-second (FEV1). Best measure			
	• • • • • • • • • • • • • • • • • • •		1.51e-04
Suffer from 'nerves' Sensitivity / hurt feelings			1.89e-02 9.94e-04 1.33e-05 4.37e-05 7.55e-04 4.47e-03
Seen doctor (GP) for nerves, anxiety, tension or depression Seen a psychiatrist for nerves, anxiety, tension or depression Seen a psychiatrist for nerves, anxiety, tension or depression Neuroticism score- Neuroticism-			1.33e-05
Seen a psychiatrist for nerVes, anxiety, tension of depression Neuronicism score-			4.3/e-05 7.55e-04
Neuroticism			4 47e 03
Mood swings-			2 08e-07
Loneliness, isolation-			5.67e-05 8.70e-06
Frequency of unenthusiasm / disinterest in last 2 weeks- Fréquency of tiredness / letharov in last 2 weeks-			8./0e-06 2.86e-07
Frequency of tenseness / restlessness in last 2 weeks			2.86e-07 1.16e-05
iniserabletes: Loneliness, isolation- Frequency of unenthusiasm / disinterest in last 2 weeks Fréquency of tiredness / testhargy in last 2 weeks Frequency of tenseness / restlessness in last 2 weeks Frequency of depressed mood in last 2 weeks Fed-up feelings Depressue sumptions			1.01e-04 8.72e-05
Depressive symptoms			1.54e-03
	-0.4 (	0.0 0.4	0.8
		r <sub>g</sub> (95 % CI)	

#### Figure 4. Forest plot of genetic correlations with psoriasis selected for Mendelian randomization analysis.

Plot contains 99 out of total 319 significant associations (Supplementary Table S3). Traits

(on the left side of the plot) are sorted by category (right side of the plot). Genetic 


correlation (rg) is indicated with a dot and the whiskers show 95 % confidence interval. P-

value of each correlation is listed on the right side of the plot. Trait names are as in the 

LDSC pipeline output, but some category names have been shortened or modified (full

- original results available in supplements).





663

664

#### Figure 5A-B. Forest plot of significant causal relationships between 665 psoriasis and other traits. 666

Mendelian randomization IVW estimates on significant causal relationships. Directions of 667

668 causality: A) exposure to psoriasis, B) psoriasis to outcome. Odds ratios and 95 %

669 confidence intervals on the x-axis, trait names on left side of the y-axis and p-values on the

670 right side of the plot.